We previously demonstrated a beneficial effect of chronic apelin supplementation on cardiac performance with reduced left ventricular preload and afterload, and increased contractile function without evidence of hypertrophy (Ashley et al., 2005). The gene discussed is APLN; the disease is cardiac hypertrophy.